Eloxx Pharmaceuticals (ELOX) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ELOX Stock Alerts $0.90 +0.06 (+7.14%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 1:34 AM | americanbankingnews.comComparing Eloxx Pharmaceuticals (NASDAQ:ELOX) and Scilex (NASDAQ:SCLX)May 17 at 2:36 AM | americanbankingnews.comEloxx Pharmaceuticals (NASDAQ:ELOX) Trading Down 2.4%April 24, 2024 | investing.comEloxx Pharmaceuticals Inc (ELOX)April 17, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finance.yahoo.comAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 16, 2024 | globenewswire.comEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesApril 5, 2024 | msn.comGene therapy and glycoside drugs offer new hope for polycystic kidney disease treatmentMarch 26, 2024 | markets.businessinsider.comNasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech ProspectsMarch 13, 2024 | finanznachrichten.deAlmirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesMarch 13, 2024 | globenewswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesMarch 13, 2024 | businesswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesFebruary 22, 2024 | benzinga.comEloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest ReportFebruary 16, 2024 | barrons.comVertex Pharmaceuticals Inc.February 6, 2024 | finance.yahoo.comEloxx Pharmaceuticals, Inc. (ELOX)January 30, 2024 | msn.comCNS Pharmaceuticals prices $4M public offeringDecember 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)December 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)December 13, 2023 | finance.yahoo.comOff the Beaten Path: 3 Delisted Stocks for The Speculative InvestorDecember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO), Crispr Therapeutics AG (CRSP) and Biomea Fusion (BMEA)November 22, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)November 14, 2023 | msn.comHoth stock jumps on positive FDA feedback on drug HT-KITNovember 13, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNovember 8, 2023 | morningstar.comEloxx Pharmaceuticals Inc ELOXOctober 9, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaSeptember 21, 2023 | seekingalpha.comEloxx Pharmaceuticals prices $2M stock offeringSeptember 19, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Announces Registered Direct Offering - Quick FactsSeptember 19, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSeptember 18, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeSeptember 8, 2023 | msn.comEloxx moves ahead with plans with gene therapy for rare kidney disorderSeptember 7, 2023 | finance.yahoo.comEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013August 30, 2023 | fool.comEloxx Pharmaceuticals (NASDAQ: ELOX)August 15, 2023 | msn.comEloxx reports all patients in Phase II Alport syndrome trial have improvedAugust 14, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeAugust 14, 2023 | msn.comEloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport SyndromeAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeJuly 12, 2023 | marketbeat.comThis Small Cap Stock Surged Over 100%Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.July 11, 2023 | msn.comEloxx, Airbnb, Tesla, PainReform, Roku: Why These 5 Stocks Are Drawing Investor Attention TodayJuly 11, 2023 | benzinga.comEloxx Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 111.3%July 11, 2023 | msn.comOppenheimer Maintains Eloxx Pharmaceuticals (ELOX) Outperform RecommendationJuly 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 03:07 PM with a stated reason of "LULD pause."July 11, 2023 | benzinga.comWhy Eloxx Pharmaceuticals (ELOX) Stock Is Soaring TuesdayJuly 11, 2023 | benzinga.comOppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55July 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 10:07 AM with a stated reason of "LULD pause."July 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 09:07 AM with a stated reason of "LULD pause."July 10, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitJune 28, 2023 | finance.yahoo.comEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02June 21, 2023 | finance.yahoo.comEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeJune 21, 2023 | finance.yahoo.comEloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA CongressJune 15, 2023 | benzinga.comFinal Data Report: Eloxx Touts Improved Lung Function For Cystic Fibrosis Candidate Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. ELOX Media Mentions By Week ELOX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELOX News Sentiment▼0.000.42▲Average Medical News Sentiment ELOX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELOX Articles This Week▼21▲ELOX Articles Average Week Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Avalon GloboCare News Today Windtree Therapeutics News Today Kiromic BioPharma News Today Finch Therapeutics Group News Today TRACON Pharmaceuticals News Today TC Biopharm News Today Acorda Therapeutics News Today Scinai Immunotherapeutics News Today Fresh Tracks Therapeutics News Today Titan Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELOX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBreaking News: Elon Musk Invents New Type of A.I. (Shocking)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
